Epigenetic silencing of MEIS2 in prostate cancer recurrence.

Maibritt NørgaardChrista HaldrupMarianne Trier BjerreSøren HøyerBenedicte UlhøiMichael BorreKarina Dalsgaard Sørensen

Published in: Clinical epigenetics (2019)

To the best of our knowledge, this is the first study to investigate, demonstrate, and independently validate a prognostic biomarker potential for MEIS2 at the transcriptional expression level and at the DNA methylation level in PC.

Keyphrases

dna methylation
prostate cancer
gene expression
poor prognosis
healthcare
genome wide
radical prostatectomy
copy number
long non coding rna
climate change